# A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

> **NCT03382639** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 256 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Luvadaxistat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03382639
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2020-12-29
- **Final completion:** 2021-01-12
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382639, "A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT03382639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*